An Open-Label, Phase I Study Assessing Pharmacokinetics And Safety/Tolerability Of USL261 (Intranasal Midazolam) In Pediatric Participants With Epilepsy

Trial Profile

An Open-Label, Phase I Study Assessing Pharmacokinetics And Safety/Tolerability Of USL261 (Intranasal Midazolam) In Pediatric Participants With Epilepsy

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Midazolam (Primary)
  • Indications Epilepsy; Partial epilepsies
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 28 Apr 2017 Results of pharmacokinetic analysis, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results of safety analysis, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 30 Nov 2016 Data from this trial will be presented at the 70th Annual Meeting of the American Epilepsy Society (AES) 2016, according to an Upsher-Smith Laboratories Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top